Today's CNN Pandemic Report on H1N1 Pushes Cannabis Science to Move Faster to Release Its Anti-Inflammatory Cannabis Drug as Similarities Between 2009 and Deadly 1918 Influenza Pandemic Cause Concern; FDA Approved Drugs Needed Now to Meet This Urgent Situ
SAN FRANCISCO, CA -- (MARKET WIRE) -- Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company, is making its anti-inflammatory formulation that targets influenza symptoms one of its top priority drugs to release, as the latest Swine flu numbers are rapidly increasing and have become quite alarming. Research indicates that the current H1N1 influenza virus has disturbing similarities to the 1918 pandemic, which killed tens of millions after World War I. Moreover, the young and otherwise healthy population that has been most susceptible to the H1N1 virus is a similar demographic to those most affected in the 1918 outbreak.
Swine flu, Bird Flu and all influenza strains that elicit excessive inflammatory immune response are targeted with Cannabis Science formulations. The company is developing its strategy for studying the effects of its cannabis lozenge on influenza deaths that are associated with an excessive inflammatory response. A hyper-inflammatory response appears to be the cause of the high mortality (63%) associated with the Avian flu (H5N1), and recent studies indicate a similar risk with the Swine flu (H1N1) as well. The World Health Organization (WHO) released the latest figures and said the virus was "unstoppable" and had become widespread enough to raise the global Swine flu alert to its highest level.
Dr. Robert Melamede, Ph.D., Cannabis Science Inc. President & CEO, observed, "Contemporary anti-viral medical technology is currently inadequate to meet the World's immediate challenges in dealing with the rapid mutations and infectivity of the numerous influenza viruses. We believe that cannabis extract-based medicines can reduce influenza deaths, and allow infected individuals to develop a strong natural immunity upon recovery."
Specifically, Cannabis Science Inc. believes that its whole-cannabis extract lozenge will inhibit the development of ARDS (Adult Respiratory Distress Syndrome) associated with deaths from both the Avian and Swine influenza infections. Dr. Melamede believes there is enormous potential value for cannabinoids that naturally prevent excessive inflammatory immune responses. He stated, "Based upon recent discoveries regarding the role that endocannabinoid system plays in maintaining human health, we may have a unique solution to the looming threat posed by deadly influenza strains, which we believe, if implemented, could save millions of lives."
Previously, Dr. Melamede urged all cannabis consumers, "If you come down with the flu, cease smoking and switch to edibles. We believe that smoking marijuana when a person has influenza will lead to some unnecessary deaths, whereas eating it can prevent unnecessary deaths."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.